Keneric Healthcare announced their partnership with Angelini Pharma Inc. This partnership will expand the reach of both companies by leveraging their clinical advocates, market share and areas of expertise.
Angelini Pharma Inc. is expanding their existing product portfolio to now include Keneric Healthcare’s RTD™ Wound Dressing (antibacterial/antifungal). RTD™ wound dressing is a proprietary highly absorbent antimicrobial foam with the only successful combination of Methylene Blue (0.25 mg/g), Gentian Violet (0.25 mg/g) and Silver Ion (7 mg/g) integrated into the polymer matrix available in the market. Healthcare providers continue to share their clinical appreciation for RTD™s ability to actively degrade and remove biofilm, to include preventing the ability of bacteria to become resistant. The successful removal of biofilm and exudate, ensures the body can resume its natural healing process leading to wound closure.
Al Henry, CEO, Keneric Healthcare stated, “Our decision to combine efforts with Angelini to further promote our RTD™ antimicrobial dressing will further increase the number of patients and practitioners that can experience RTD™s proven efficacy.”
Todd Maddock, the CEO of Angelini U.S. stated, “We are excited to add Keneric’s RTD Dressing to our product portfolio. We look to provide healthcare professionals and patients with a range of wound treatment options based on innovative technologies like Keneric’s RTD™ Wound Dressing.”
Keneric Healthcare is a medical device company, headquartered in Irving, Texas, that is recognized by healthcare executives and clinicians alike for the development of innovative products that improve care, increase clinician efficiency and streamline facility expenditures.
Angelini is a privately-held, mid-sized international manufacturer and marketer of pharmaceutical and healthcare products in the pharmaceutical, infection control, wound care, dialysis, and mass-market segments. Founded in Italy in 1919, the group has operations in 20 countries and employs 5,000 people.
